160 related articles for article (PubMed ID: 34655170)
1. A Promising Option for ADA-SCID Patients.
Am J Med Genet A; 2021 Nov; 185(11):3184-3185. PubMed ID: 34655170
[No Abstract] [Full Text] [Related]
2. Gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency.
Montiel-Equihua CA; Thrasher AJ; Gaspar HB
Curr Gene Ther; 2012 Feb; 12(1):57-65. PubMed ID: 22348551
[TBL] [Abstract][Full Text] [Related]
3. ADA-SCID Gene Therapy Endorsed By European Medicines Agency For Marketing Authorization.
Ylä-Herttuala S
Mol Ther; 2016 Jun; 24(6):1013-1014. PubMed ID: 27324442
[No Abstract] [Full Text] [Related]
4. Gene therapy for ADA-SCID, the first marketing approval of an
Aiuti A; Roncarolo MG; Naldini L
EMBO Mol Med; 2017 Jun; 9(6):737-740. PubMed ID: 28396566
[TBL] [Abstract][Full Text] [Related]
5. Promising Results with Ex Vivo Lentiviral HSPC Gene Therapy in ADA-SCID.
Am J Med Genet A; 2021 Aug; 185(8):2291-2292. PubMed ID: 34240545
[No Abstract] [Full Text] [Related]
6. Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients.
Cooper AR; Lill GR; Shaw K; Carbonaro-Sarracino DA; Davila A; Sokolic R; Candotti F; Pellegrini M; Kohn DB
Blood; 2017 May; 129(19):2624-2635. PubMed ID: 28351939
[TBL] [Abstract][Full Text] [Related]
7. Investor Outlook: Rising from the Ashes; GSK's European Approval of Strimvelis for ADA-SCID.
Schimmer J; Breazzano S
Hum Gene Ther Clin Dev; 2016 Jun; 27(2):57-61. PubMed ID: 27267267
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy's out-of-body experience.
Scott CT; DeFrancesco L
Nat Biotechnol; 2016 Jun; 34(6):600-7. PubMed ID: 27281416
[No Abstract] [Full Text] [Related]
9. EMA greenlights second gene therapy.
Mullard A
Nat Rev Drug Discov; 2016 May; 15(5):299. PubMed ID: 27139988
[No Abstract] [Full Text] [Related]
10. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency.
Carbonaro DA; Zhang L; Jin X; Montiel-Equihua C; Geiger S; Carmo M; Cooper A; Fairbanks L; Kaufman ML; Sebire NJ; Hollis RP; Blundell MP; Senadheera S; Fu PY; Sahaghian A; Chan RY; Wang X; Cornetta K; Thrasher AJ; Kohn DB; Gaspar HB
Mol Ther; 2014 Mar; 22(3):607-622. PubMed ID: 24256635
[TBL] [Abstract][Full Text] [Related]
11. A Journey in the Development of Gene Therapy for Inherited Disorders of the Bone Marrow.
Kohn D; Wilson JM
Hum Gene Ther Clin Dev; 2015 Dec; 26(4):203-7. PubMed ID: 26684443
[No Abstract] [Full Text] [Related]
12. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice.
Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV
Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446
[TBL] [Abstract][Full Text] [Related]
13. Recombinant adeno-associated virus-mediated gene transfer for the potential therapy of adenosine deaminase-deficient severe combined immune deficiency.
Silver JN; Elder M; Conlon T; Cruz P; Wright AJ; Srivastava A; Flotte TR
Hum Gene Ther; 2011 Aug; 22(8):935-49. PubMed ID: 21142972
[TBL] [Abstract][Full Text] [Related]
14. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
[TBL] [Abstract][Full Text] [Related]
15. Built to last: gene therapy for ADA SCID.
Pai SY
Blood; 2021 Oct; 138(15):1287-1288. PubMed ID: 34647983
[No Abstract] [Full Text] [Related]
16. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency.
Cicalese MP; Ferrua F; Castagnaro L; Pajno R; Barzaghi F; Giannelli S; Dionisio F; Brigida I; Bonopane M; Casiraghi M; Tabucchi A; Carlucci F; Grunebaum E; Adeli M; Bredius RG; Puck JM; Stepensky P; Tezcan I; Rolfe K; De Boever E; Reinhardt RR; Appleby J; Ciceri F; Roncarolo MG; Aiuti A
Blood; 2016 Jul; 128(1):45-54. PubMed ID: 27129325
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Outcome of Adenosine Deaminase-Deficient Patients-a Single-Center Experience.
Scott O; Kim VH; Reid B; Pham-Huy A; Atkinson AR; Aiuti A; Grunebaum E
J Clin Immunol; 2017 Aug; 37(6):582-591. PubMed ID: 28748310
[TBL] [Abstract][Full Text] [Related]
18. Spectrum of mutations in a cohort of UK patients with ADA deficient SCID: Segregation of genotypes with specific ethnicities.
Adams SP; Wilson M; Harb E; Fairbanks L; Xu-Bayford J; Brown L; Kearney L; Madkaikar M; Bobby Gaspar H
Clin Immunol; 2015 Dec; 161(2):174-9. PubMed ID: 26255240
[TBL] [Abstract][Full Text] [Related]
19. Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety.
Cicalese MP; Ferrua F; Castagnaro L; Rolfe K; De Boever E; Reinhardt RR; Appleby J; Roncarolo MG; Aiuti A
Mol Ther; 2018 Mar; 26(3):917-931. PubMed ID: 29433935
[TBL] [Abstract][Full Text] [Related]
20. Deficiency of adenosine deaminase 2: a case series revealing clinical manifestations, genotypes and treatment outcomes from Turkey.
Kisla Ekinci RM; Balci S; Hershfield M; Bisgin A; Dogruel D; Altintas DU; Yilmaz M
Rheumatology (Oxford); 2020 Jan; 59(1):254-256. PubMed ID: 31292637
[No Abstract] [Full Text] [Related]
[Next] [New Search]